Scholarlink

Background <p>Systemic inflammatory responses play a crucial role in cancer progression, and peripheral blood biomarkers have emerged as potential prognostic and predictive markers in various malignancies. This study evaluated the efficacy of serial peripheral blood biomarkers as independent prognostic and predictive indicators in patients with breast cancer who received neoadjuvant chemotherapy.</p> Methods <p>This retrospective cohort study investigated the prognostic value of peripheral blood biomarkers, including red cell distribution width (RDW), RDW to platelet count ratio (RPR), platelet count (PLT), platelet distribution width (PDW), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), PDW to platelet count ratio (PDW/P), and mean platelet volume (MPV) in patients with breast cancer treated with neoadjuvant chemotherapy at a single institution, from 2007 to 2013. Blood samples were collected at diagnosis, after neoadjuvant chemotherapy, after surgery, and 6–12 months postoperatively. Statistical analyses included t-tests, chi-square tests, Cox regression for survival, and logistic regression for clinical responses to neoadjuvant chemotherapy. Longitudinal changes in biomarkers were analyzed using linear mixed-effects models.</p> Results <p>Among 1139 patients receiving neoadjuvant chemotherapy, 15.2% achieved pathological complete response (pCR). Tumor size, histologic grade, and molecular subtype were independent predictors of pCR, whereas baseline hematologic biomarkers did not predict pCR. At diagnosis, elevated PDW, NLR, and MPV were associated with worse disease-free survival (DFS) and breast cancer-specific survival (BCSS) in multivariate analysis. During follow-up, elevated RDW, RPR, PDW, PDW/P, NLR, and MPV remained significant predictors of poor prognosis. NLR consistently predicted worse DFS and BCSS (HRs, 1.06; <i>p</i> &lt; 0.001). Time-sequence analysis showed significant changes in NLR, PDW, and MPV over time (all <i>p</i> &lt; 0.001), with persistently higher NLR in the recurrence group (interaction <i>p</i> = 0.0003).</p> Conclusions <p>Although baseline hematologic biomarkers did not predict pCR, several biomarkers such as NLR, PDW, and MPV demonstrated strong prognostic value for long-term survival. Notably, NLR also showed prognostic relevance through longitudinal changes, supporting its potential role as a dynamic biomarker.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical significance of peripheral blood parameters as a prognostic biomarker in patients receiving neoadjuvant chemotherapy for breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月3日

查看全文
  • Tae-in Yoon,
  • Seunghee Baek,
  • Ji hyeon Lee,
  • Tae Kyung Yoo,
  • Jisun Kim,
  • Il Yong Chung,
  • Beom Seok Ko,
  • Hee Jeong Kim,
  • Jong Won Lee,
  • Byung Ho Son,
  • Sae Byul Lee

摘要

Background

Systemic inflammatory responses play a crucial role in cancer progression, and peripheral blood biomarkers have emerged as potential prognostic and predictive markers in various malignancies. This study evaluated the efficacy of serial peripheral blood biomarkers as independent prognostic and predictive indicators in patients with breast cancer who received neoadjuvant chemotherapy.

Methods

This retrospective cohort study investigated the prognostic value of peripheral blood biomarkers, including red cell distribution width (RDW), RDW to platelet count ratio (RPR), platelet count (PLT), platelet distribution width (PDW), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), PDW to platelet count ratio (PDW/P), and mean platelet volume (MPV) in patients with breast cancer treated with neoadjuvant chemotherapy at a single institution, from 2007 to 2013. Blood samples were collected at diagnosis, after neoadjuvant chemotherapy, after surgery, and 6–12 months postoperatively. Statistical analyses included t-tests, chi-square tests, Cox regression for survival, and logistic regression for clinical responses to neoadjuvant chemotherapy. Longitudinal changes in biomarkers were analyzed using linear mixed-effects models.

Results

Among 1139 patients receiving neoadjuvant chemotherapy, 15.2% achieved pathological complete response (pCR). Tumor size, histologic grade, and molecular subtype were independent predictors of pCR, whereas baseline hematologic biomarkers did not predict pCR. At diagnosis, elevated PDW, NLR, and MPV were associated with worse disease-free survival (DFS) and breast cancer-specific survival (BCSS) in multivariate analysis. During follow-up, elevated RDW, RPR, PDW, PDW/P, NLR, and MPV remained significant predictors of poor prognosis. NLR consistently predicted worse DFS and BCSS (HRs, 1.06; p < 0.001). Time-sequence analysis showed significant changes in NLR, PDW, and MPV over time (all p < 0.001), with persistently higher NLR in the recurrence group (interaction p = 0.0003).

Conclusions

Although baseline hematologic biomarkers did not predict pCR, several biomarkers such as NLR, PDW, and MPV demonstrated strong prognostic value for long-term survival. Notably, NLR also showed prognostic relevance through longitudinal changes, supporting its potential role as a dynamic biomarker.